SUPERIOR INFLUENCE OF THE MOTHER ON BODY SIZE IN RECIPROCAL HYBRIDS.

W. Castle

DOI: https://doi.org/10.1126/SCIENCE.83.2165.627

IF: 56.9

1936-06-26

Science

Abstract:

What problem does this paper attempt to address?

Efficacy of Different Doses of Nitroglycerin Combined with Clopidogrel in the Treatment of Angina Pectoris

Jin Lin

2010-01-01

Abstract:Objective To observe the clinical efficacy of the routine drug combination with nitroglycerin for coronary heart disease angina pectoris.MethodTotal 75 patients were randomly divided into the treatment group(25 cases of high-dose group and 25 cases of small-dose group)and the control group(25 cases).The control group was given conventional therapy,and the treatment group received nitrog lycerin on the basis of conventional therapy.ResultsThe total effective rate of treating angina pectoris and ECG were better than the control group.After treatment,compared with the control group,liver,kidney functions and the three conventional testing in the treatment group showed no significant differences.ConclusionThe combined therapy is more effective,and with no serious side effects.
Violence against young women attending primary care services in Spain: prevalence and health consequences.

D. Martín-Baena,Isabel Montero-Piñar,V. Escribà-Agüir,C. Vives‐Cases

DOI: https://doi.org/10.1093/fampra/cmv017

2015-08-01

Family Practice

Abstract:BACKGROUND There are a significant number of studies assessing the negative health consequences of violence against women. However, a limited number of studies analyse the health consequences of violence committed against young women by different types of aggressors. OBJECTIVES The goal of this study is to assess the prevalence of interpersonal violence against young women in Spain and analyse its impact on the physical and mental health of the victims. METHODS A total of 1076 women aged 18-25 years attending Spanish primary care services were selected. We estimated the prevalence of interpersonal violence and compared the health data and demographic characteristics of abused and non-abused young women, multi-logistic regression models were fitted. The Wald test was used to assess whether there were differences in the negative health consequences of intimate partner (IPV) versus non-IPV. RESULTS As many as 27.6% young women reported a history of abuse, of whom 42.7% had been assaulted by their partner, 41.1% by someone other than their partner and 16.2% both by their partner and another person. The distribution of social and demographic characteristics was similar for IPV and non-IPV victims. Young abused women were three times more likely to suffer psychological distress and have somatic complaints, and they were four times more likely to use medication as compared to non-abused women. CONCLUSION Our results suggest that all forms of violence compromise young women's health seriously. Including patients' history of abuse in their health record may help make more informed clinical decisions and provide a more integrated care.
Functional serotonin 5–HTTLPR polymorphism is a risk factor for migraine with aura

B. Borroni,Cristina Brambilla,P. Liberini,R. Rao,S. Archetti,S. Gipponi,Giorgio Dalla Volta,A. Padovani

DOI: https://doi.org/10.1007/s10194-005-0179-9

2005-07-20

The Journal of Headache and Pain

Abstract:
Transdermal clonidine in mild hypertension. A randomized, double-blind, placebo-controlled trial

S Popli,J T Daugirdas,J A Neubauer,B Hockenberry,J E Hano,T S Ing

Abstract:In 30 patients with mild essential hypertension, clonidine hydrochloride was delivered from a skin patch reservoir designed to release medication at a constant rate for seven days. After a four-week washout period, patients were randomized (double-blind) into a clonidine- or a placebo-treated group. Clonidine or placebo was then given for five weeks, followed by a two-week washout period to assess withdrawal from treatment. Blood pressure was controlled in 11 of 15 clonidine-treated patients but in only four of 15 placebo-treated patients. The clonidine-treated group evidenced larger decreases in both systolic and diastolic blood pressures. In the clonidine-treated group, blood pressures and plasma clonidine levels were stable throughout a representative seven-day period. Besides mild skin irritation with both clonidine and placebo patches, few side effects were observed. After discontinuation of clonidine administration, plasma levels declined in a non-log linear manner. There was no rebound hypertension. The results suggest that clonidine delivered transdermally is safe and effective for control of mild essential hypertension.
Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus

D Giugliano,R Acampora,R Marfella,C La Marca,M Marfella,F Nappo,F D'Onofrio

DOI: https://doi.org/10.1016/s0895-7061(97)00319-1

Abstract:The aim of this study was to evaluate the effect of transdermal clonidine on hemodynamic and metabolic parameters in patients who have elevated blood pressure and non-insulin-dependent diabetes mellitus (NIDDM). After a 2-week run in placebo period, 20 NIDDM patients who had diastolic blood pressure in the range of 90 to 105 mm Hg underwent a randomized, single blind, placebo controlled, cross-over study of 4 week treatment with clonidine (transdermal patch 2.5 mg/week) or placebo (inactive patch). Compared with placebo, clonidine significantly reduced systolic (153 +/- 6 v 163 +/- 8) and diastolic (88 +/- 2 v 98 +/- 3.5 mm Hg, P = .001) blood pressure, left ventricular mass (94 +/- 11 v 99 +/- 12 g/m2, P < .01) and fasting glucose levels. Total glucose disposal (glucose clamp) was 6.5 +/- 1.5 with placebo and 7.1 +/- 1.6 mg/kg/min with clonidine (P < .01). Oxidative glucose disposal (indirect calorimetry) was also greater after clonidine. Plasma glucose, insulin, and C-peptide responses following oral glucose (75 g) were significantly lower after clonidine, as well as urinary albumin excretion. Transdermal clonidine is effective in reducing blood pressure in hypertensive NIDDM patients and is well tolerated. It may be useful to reduce the cardiovascular impact of hypertension in diabetes mellitus.
Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma.

F. Boas,Bao Do,J. Louie,N. Kothary,G. Hwang,W. Kuo,D. Hovsepian,M. Kantrowitz,D. Sze

DOI: https://doi.org/10.1016/j.jvir.2014.09.013

IF: 3.682

Journal of Vascular and Interventional Radiology

Abstract:
Genetics of drought adaptation in Arabidopsis thaliana: I. Pleiotropy contributes to genetic correlations among ecological traits

J. McKay,J. H. Richards,T. Mitchell-Olds

DOI: https://doi.org/10.1046/j.1365-294X.2003.01833.x

IF: 6.622

2003-05-01

Molecular Ecology

Abstract:We examined patterns of genetic variance and covariance in two traits (i) carbon stable isotope ratio δ13C (dehydration avoidance) and (ii) time to flowering (drought escape), both of which are putative adaptations to local water availability. Greenhouse screening of 39 genotypes of Arabidopsis thaliana native to habitats spanning a wide range of climatic conditions, revealed a highly significant positive genetic correlation between δ13C and flowering time. Studies in a range of C3 annuals have also reported large positive correlations, suggesting the presence of a genetically based trade‐off between mechanisms of dehydration avoidance (δ13C) and drought escape (early flowering). We examined the contribution of pleiotropy by using a combination of mutant and near‐isogenic lines to test for positive mutational covariance between δ13C and flowering time. Ecophysiological mutants generally showed variation in δ13C but not flowering time. However, flowering time mutants generally demonstrated pleiotropic effects consistent with natural variation. Mutations that caused later flowering also typically resulted in less negative δ13C and thus probably higher water use efficiency. We found strong evidence for pleiotropy using near‐isogenic lines of FRIGIDA and FLOWERING LOCUS C, cloned loci known to be responsible for natural variation in flowering time. These data suggest the correlated evolution of δ13C and flowering time is explained in part by the fixation of pleiotropic alleles that alter both δ13C and time to flowering.
Efficacy and safety of two different galenic formulations of a transdermal clonidine system in the treatment of hypertension

R E Kolloch,L Mehlburger,H Schumacher,B O Göbel

DOI: https://doi.org/10.1007/BF01829456

Abstract:The efficacy and safety of two different galenic formulations of transdermal clonidine systems were compared in 905 patients with mild to moderate essential hypertension during a 12 weeks observation period. 449 patients were treated with the matrix controlled clonidine transdermal (C-TD) system and 456 patients with the membrane controlled clonidine system (C-TTS). The mean blood pressure was reduced from 168/102 mmHg to 146/87 mmHg in the C-TD and from 169/102 mmHg to 148/88 mmHg in the C-TTS group. There was no difference in the response rate. The pattern of systemic side-effects appeared to correspond to those seen during oral clonidine treatment but with a lower frequency and intensity. The C-TD patch improved skin tolerability and the drop-out rate due to skin reactions was 2.2 times lower compared with the C-TTS group. Local skin reactions led to withdrawal in 35 of 449 C-TD treated and in 79 of 456 C-TTS treated patients. In conclusion, the improved carrier system for the transdermal clonidine treatment reduced local side-effects which in turn may further enhance acceptability and compliance in treated patients.
Fetal Growth Restriction Is Associated With Prioritization of Umbilical Blood Flow to the Left Hepatic Lobe at the Expense of the Right Lobe

J. Kessler,S. Rasmussen,K. Godfrey,M. Hanson,T. Kiserud

DOI: https://doi.org/10.1203/PDR.0b013e3181a29077

IF: 3.953

2009-07-01

Pediatric Research

Abstract:Eighty to 85% of the venous perfusion to the fetal liver is from the umbilical vein, the rest from the portal vein. Umbilical venous flow to the liver is essential for intrauterine growth, and is impaired in placental insufficiency. We hypothesized that in growth-restricted fetuses portal blood flow compensates for insufficient umbilical blood flow to the liver. In 29 fetuses with fetal growth restriction (estimated fetal weight ≤5th percentile), we used ultrasound to measure blood flows in the umbilical vein, ductus venosus, left portal vein, and main portal stem. Compared with normal fetuses, both absolute and normalized total venous liver blood flows were reduced in growth-restricted fetuses, related to the degree of placental compromise and equally affecting both liver lobes. However, portal replaced umbilical flow to the right lobe, in a manner graded according to placental vascular resistance; in extreme cases, the right lobe received no umbilical perfusion. In fetal growth restriction, the liver suffers from venous hypoperfusion, and portal blood partially replaces umbilical flow to the right lobe; this will result in right liver lobe hypoxemia. This striking prioritization in nutrient delivery of left over right lobes suggests an adaptive response to poor placental perfusion that may have functional consequences.
A double-blind comparison of transdermal clonidine and oral captopril in essential hypertension

F G McMahon,A K Jain,R Vargas,J Fillingim

Abstract:In a double-blind study, patients with mild essential hypertension were randomly assigned to treatment with transdermal clonidine or oral captopril. After a two- to three-week titration period, blood pressure decreased significantly from 146.3/95.4 to 134.7/85.1 mmHg in the 33 clonidine-treated patients and from 143.0/96.1 to 134.8/87.1 mmHg in the 35 captopril-treated patients; the mean daily doses were 0.2 mg (equivalent) of clonidine and 122.9 mg of captopril. After eight weeks of treatment, blood pressures were reduced to 132.9/85.2 mmHg in the clonidine group (n = 22) and 131.2/82.5 mmHg in the captopril group (n = 16). In black patients, blood pressure reductions were greater with clonidine than with captopril. Four patients were withdrawn from treatment because of side effects in the clonidine group and one in the captopril group. No between-group differences were found in the responses to a quality-of-life questionnaire completed before and after treatment. The clonidine patches were worn during 99% of patient-weeks of treatment; captopril was taken as directed during 64% of patient-weeks of treatment. It is concluded that transdermal clonidine is safe and effective and well accepted by hypertensive patients.
Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure

Cyndya Shibao,Alfredo Gamboa,Robert Abraham,Satish R Raj,Andre Diedrich,Bonnie Black,David Robertson,Italo Biaggioni

DOI: https://doi.org/10.1161/01.HYP.0000199982.71858.11

IF: 9.8968

Hypertension

Abstract:Patients with autonomic failure are disabled by orthostatic hypotension, which can be worsened by the nighttime pressure natriuresis induced by associated supine hypertension. Several pharmacological agents are available that effectively reduce nighttime hypertension, but none of them prevent pressure natriuresis. Because hypertension of autonomic failure can be driven by residual sympathetic tone, we hypothesized that clonidine would be effective in reducing blood pressure (BP) and nocturnal natriuresis. Therefore, we determined the effect of placebo, 0.1 mg clonidine, and 0.1-mg/h nitroglycerin transdermal patch on supine BP, orthostatic hypotension, and pressure natriuresis in 23 patients with primary autonomic failure and supine hypertension. Medications were given at 8:00 PM, and BP was recorded every 2 hours for 12 hours. The maximal decrease in BP was seen 6 to 8 hours after drug administration and was similar to clonidine and nitroglycerin (-29+/-9 and -30+/-10 mm Hg, respectively), as was the average fall in BP throughout the night. However, only clonidine effectively reduced nocturnal natriuresis (-0.09 mmol/mg Cr; 95% CI, -0.13 to -0.04; P=0.004), but this was not associated with improvement in morning orthostatic hypotension because of a residual hypotensive effect. The decrease in BP induced by clonidine was modestly but significantly correlated with the magnitude of residual sympathetic tone determined in 10 subjects by the fall in BP induced by ganglionic blockade (r=0.66; P=0.043). These results are consistent with residual sympathetic tone contributing to supine hypertension in autonomic failure, which can be targeted with clonidine to decrease BP and nocturnal natriuresis.
Computational Prediction of the Protonation Sites of Ac-Lys-(Ala)n-Lys-NH2 Peptides through Conceptual DFT Descriptors

S. Sastre,J. Frau,D. Glossman‐Mitnik

DOI: https://doi.org/10.3390/molecules22030458

IF: 4.6

2017-03-01

Molecules

Abstract:Six density functionals (M11, M11L, MN12L, MN12SX, N12, and N12SX) in connection with the Def2TZVP basis set and the SMD solvation model (water as a solvent) have been assessed for the calculation of the molecular structure and properties of several peptides with the general formula Ac-Lys-(Ala)n-Lys-NH2, with n = 0 to 5. The chemical reactivity descriptors for these systems have been calculated through Conceptual density functional theory (DFT). The active sites for nucleophilic and electrophilic attacks have been chosen by relating them to the Fukui function indices, the condensed dual descriptor Δf(r), and the electrophilic Parr functions. The results allowed the prediction of the protonation sites of the peptides and rendered a qualitative explanation of the difference in pKa of the two Lys groups.
Patient acceptance of transdermal clonidine. A retrospective review of 25 patients

S W Chen,D G Vidt

DOI: https://doi.org/10.3949/ccjm.56.1.21

Abstract:The clinical records of 25 ambulatory patients who received clonidine (Catapres-TTS) for periods of one to 19 months were reviewed to determine the effectiveness and long-term patient tolerance of this transdermal antihypertensive medication. In 11 patients with mild to moderate hypertension in whom Catapres-TTS was initiated as monotherapy or added to an oral diuretic, significant blood pressure reduction was observed during the initial four weeks of therapy. In 14 patients who had more severe hypertension and who were receiving multiple antihypertensive agents, Catapres-TTS did not result in significantly reduced blood pressure. Daily home blood pressure measurements in five patients showed no day-to-day variations in blood pressure during the seven days each patch was worn. Catapres-TTS was discontinued in 11 patients because of localized contact dermatitis (six patients), patient dissatisfaction (three patients), and physician's decision (two patients). In three patients, localized contact dermatitis developed only after continuous use for periods of four to 13 months. Other adverse effects such as drowsiness and dry mouth were less apparent than with comparable doses of oral clonidine, and did not necessitate discontinuation of therapy in any patient. Black patients appear to tolerate Catapres-TTS better than whites. Catapres-TTS appears to be effective in patients with mild to moderate hypertension and may be a useful alternative to oral clonidine in patients experiencing drowsiness or dry mouth with the oral preparation.
One year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension--a multicentre open label study. The Antihypertensive Patch Italian Study (APIS) Investigators

Abstract:The clonidine patch offers for the first time the unique possibility of a once-a-week transdermal therapy of hypertension due to direct absorption of clonidine through the skin. The present study investigates the efficacy and safety of the transdermal administration on a sample of the Italian population. 101 patients entered the study, 51 male, 50 female (mean age: 53 years, SD +/- 10; range: 30-71 years), they were given clonidine by a therapeutical transdermal system as starting dosage. If blood pressure was not adequately controlled (DBP < 90 or 10 mmHg decreased from baseline value) the dosage was increased on a 2 week basis assessment. The patients were then followed for 12 months after the start of treatment. The decrease in both systolic and diastolic blood pressure continued up to one month after start of treatment and remained constant for at least 9 months. A total of 70% of the patients were controlled by the antihypertensive treatment as monotherapy, while in 6% additional combination with a diuretic lead to blood pressure control. 5% of the patients showed no reduction in blood pressure at the end of the titration phase. 24 (23%) patients complained of skin reaction; 21 patients of these (ten male, eleven female) were withdrawn from the trial due to predefined skin reaction criteria. No serious side effects have been observed during the run of the study. No rebound phenomena occurred in the week after treatment discontinuation. It is concluded that the transdermal treatment of hypertension with a clonidine containing transdermal system is therapeutically effective and probably associated with a high acceptability and increased compliance.
Effects of transdermal clonidine in young and elderly patients with mild hypertension: evaluation by three noninvasive methods of blood pressure measurement

X Jeunemaitre,E Ged,M B Ducrocq,F Alhenc-Gelas,P Corvol,J Menard

DOI: https://doi.org/10.1097/00005344-198708000-00005

Abstract:The efficiency of the clonidine transdermal therapeutic system was assessed in a group of patients under 35 years of age and in another group of patients over 60 years of age. The patients in both groups had mild uncomplicated hypertension. Blood pressure (BP) was measured by the three following methods: by the physician; by an automatic device at the outpatient clinic; and by the patient at home. Seventeen young patients (mean age, 26 years) and 18 elderly patients (mean age, 68.5 years) were included in a double-blind crossover study comprising four periods of 2 weeks each, during which patients were given, weekly, either placebo or one and then two transdermal clonidine patches containing 2.5 mg of the drug. In the younger group, the average systolic and diastolic BPs measured by the physician after administration of two clonidine patches were, respectively, 4.9 and 5.9 mm Hg lower than after placebo (p less than 0.05). The absolute drop was more significant in the older group (9.3 and 6.0 mm Hg; p less than 0.01). In the young group, placebo markedly reduced systolic BP (9.8 mm Hg; p less than 0.01), and comparison of the three methods of BP measurement demonstrated their great reactivity to the physician's presence. Nine young and eight elderly patients received clonidine treatment for an average duration of 9 +/- 5 months. Six cases of skin reactions occurred and limited the usefulness of the clonidine transdermal system used in this study.
Accelerated Thermal Cycling Test of Microencapsulated Paraffin Wax/Polyaniline Made by Simple Preparation Method for Solar Thermal Energy Storage

M. Silakhori,M. S. Naghavi,H. Metselaar,T. Mahlia,H. Fauzi,M. Mehrali

DOI: https://doi.org/10.3390/ma6051608

IF: 3.4

2013-04-29

Materials

Abstract:Microencapsulated paraffin wax/polyaniline was prepared using a simple in situ polymerization technique, and its performance characteristics were investigated. Weight losses of samples were determined by Thermal Gravimetry Analysis (TGA). The microencapsulated samples with 23% and 49% paraffin showed less decomposition after 330 °C than with higher percentage of paraffin. These samples were then subjected to a thermal cycling test. Thermal properties of microencapsulated paraffin wax were evaluated by Differential Scanning Calorimeter (DSC). Structure stability and compatibility of core and coating materials were also tested by Fourier transform infrared spectrophotometer (FTIR), and the surface morphology of the samples are shown by Field Emission Scanning Electron Microscopy (FESEM). It has been found that the microencapsulated paraffin waxes show little change in the latent heat of fusion and melting temperature after one thousand thermal recycles. Besides, the chemical characteristics and structural profile remained constant after one thousand thermal cycling tests. Therefore, microencapsulated paraffin wax/polyaniline is a stable material that can be used for thermal energy storage systems.
An Architecture and Formalism for Handling Modular Ontologies

F. Ensan

2008-07-13

Abstract:The goal of my ongoing work is to provide an architecture for developing and manipulating modular ontologies in such a way that each ontology module can plug into or unplug from an ontology. This architecture builds on top of a fundamental formalism for modular ontologies. Through this formalism we are able to define mechanisms for integrating different modules and develop algorithms for reasoning over the integrated modules. The resolution of inconsistencies arisen by conflicting axioms in different modules as well as the investigation of the impact of changes in a module on the other ontology modules are two important issues that need to be taken into consideration during the development of the formalism. Here, we briefty review the overall structure of the research work that I intended to conduct.
Efficacy and tolerability of long-acting nifedipine GITSOROS monotherapy or combination therapy in hypertensive patients: Results of a 12-week international, prospective, multicentre, observational study

Kwo-Chang Ueng,Sun Ningling,Abd El Maksod,Kuan-Yu Hung,Yin Yuehui

DOI: https://doi.org/10.2165/11588970-000000000-00000

2011-01-01

Clinical Drug Investigation

Abstract:Background: Achieving the maximum reduction in cardiovascular morbidity and mortality is the primary goal of blood pressure (BP) control. Current guidelines recommend several antihypertensive classes as first-line therapy for this purpose but the decision on which agent/s to use will likely be based upon the treating physician's clinical experience. Observational studies provide a useful way of ascertaining the efficacy and tolerability of an antihypertensive in a real-life clinical setting. Objective: The aim of this observational study was to determine the efficacy, tolerability and physician/patient satisfaction with long-acting nifedipine (gastrointestinal therapeutic system [GITS]/osmotic-controlled release oral delivery system [OROS]) in a large multinational cohort of hypertensive patients. Methods: This observational study was conducted in adults (aged >= 18 years) with previously untreated or treated hypertension. The decision to prescribe nifedipine 30 or 60 mg once daily was made by the treating physician. Patients then attended up to three clinic visits any time over a 12-week period when medication could be up- or down-titrated or switched. The mean reduction in systolic BP (SBP)/diastolic BP (DBP) from first visit and whether target BP (<140/<90 mmHg or <130/<80 mmHg [for patients with diabetes mellitus]) had been achieved were recorded at the final visit and stratified according to hypertension grade and presence of cardiovascular risk factors. Subjective assessment of efficacy was reported by physicians and patients. All adverse events and their possible relationship to study drug were recorded. All assessments were performed on patients who received at least one dose of nifedipine GITS/OROS. Results: A total of 14 344 patients received nifedipine GITS/OROS treatment (58.7% male; 77.7% non-diabetic; mean age 57.5 years); 14 266 had at least one follow-up visit over a mean 10.2-week period, and 8000 patients had three visits over a mean 12-week period. Initially, 12 826 (89.4%) patients received nifedipine 30 mg, and 6912 patients (48.2%) overall received concomitant antihypertensive agents. The overall mean reduction in SBP/DBP was -27.7/-14.1 mmHg; BP reduction was linked to hypertension grade, age, the presence of five or more cardiovascular risk factors, and prior treatment. Target BP was achieved in 2485/7432 patients (33.4%) receiving nifedipine GITS/OROS monotherapy and in 1751/6912 (25.3%) receiving combination therapy (i.e. GITS/OROS plus any other antihypertensive agent). Non-diabetic patients with moderate (n = 3413) and high (n=1138) risk reached their target BP goal in 62.5% and 54.2% of cases, respectively; the corresponding values in diabetic patients (moderate-added risk n = 8; high-added risk n = 684) were 75.0% and 54.8%, respectively. A total of 229 patients (1.6%) reported experiencing 286 adverse events. Physician/patient satisfaction with treatment was high. Conclusion: Long-acting nifedipine GITS/OROS, alone or in combination with other antihypertensive agents, provides effective and well tolerated treatment of hypertension in a broad spectrum of patients routinely seen in day-to-day clinical practice.
Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL)

Rong Lv,Jianghua Chen,Huamin Wang,Jijun Wang,Hong Cheng,Rong Li,Wei Li,Tao Zhang,Lixin Wei,Qinkai Chen,Jian Huang,Feng Yu,Shizhong Shen,Henglan Wu,Cuihong Liu,Fuyuan Hong,Jie Liu,Xiaoru Zhang,Hua Xiao,Wenbin Song

DOI: https://doi.org/10.1007/s12325-021-01850-3

Abstract:Introduction: Achieving target blood pressure (BP) goals in patients with chronic kidney disease (CKD) and uncontrolled hypertension is a challenge. Various studies have shown the efficacy of nifedipine gastrointestinal therapeutic system (GITS) 60 mg in patients with hypertension. However, there is a paucity of clinical studies in patients with CKD. Hence, we conducted this study to evaluate the effectiveness and tolerability of nifedipine GITS 60 mg in Chinese patients with CKD and uncontrolled hypertension in real-world clinical settings. Methods: In a prospective, multicenter, observational study, Chinese patients with CKD and uncontrolled hypertension were given nifedipine GITS 60 mg with a primary endpoint of change in office systolic BP (SBP) at 12 weeks. The secondary endpoints included changes at 12 weeks in office diastolic BP (DBP), office SBP and DBP in SBP subgroups (140-160 mmHg and ≥ 160 mmHg) and CKD stages subgroups, SBP and DBP control rate, and the adverse events (AEs). Statistical analysis was performed using SAS® version 9.4. Results: In total, 871 and 622 patients were included in the safety analysis set and efficacy analysis set respectively. The mean office SBP and DBP at baseline were 162.9 and 97.3 mmHg, respectively. At week 12, the mean change in SBP was - 24.0 mmHg (95% confidence interval [CI] - 25.32, - 22.65 mmHg); after missing data were accounted for, it was - 23.9 mmHg (95% CI - 25.25, - 22.60 mmHg). Marked decreases in DBP, and office SBP and DBP in baseline SBP subgroups as well as CKD stages were observed at week 12. The BP control rate at week 12 was 50.0%. Twenty-three (2.6%) patients reported at least one drug-related AEs. No event of hypotension or death occurred during the study. Conclusion: Nifedipine GITS 60 mg showed effectiveness and tolerability in reducing office SBP and DBP in Chinese patients with CKD and uncontrolled hypertension. Trial registration: ClinicalTrials.gov identifier NCT03194633.
Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS

W H Frishman,D Sherman,D A Feinfeld

Abstract:Innovative drug delivery systems have been developed for nifedipine and clonidine that prolong the pharmacologic activity of the medications, allowing once daily dosing. The nifedipine-GITS (gastrointestinal therapeutic system) tablet formulation and the clonidine-TTS (transcutaneous delivery system) patch may also reduce side effects in patients while preserving the therapeutic efficacy of the origin drug formulations (nifedipie capsule, clonidine tablet).

SUPERIOR INFLUENCE OF THE MOTHER ON BODY SIZE IN RECIPROCAL HYBRIDS.

Efficacy of Different Doses of Nitroglycerin Combined with Clopidogrel in the Treatment of Angina Pectoris

Violence against young women attending primary care services in Spain: prevalence and health consequences.

Functional serotonin 5–HTTLPR polymorphism is a risk factor for migraine with aura

Transdermal clonidine in mild hypertension. A randomized, double-blind, placebo-controlled trial

Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus

Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma.

Genetics of drought adaptation in Arabidopsis thaliana: I. Pleiotropy contributes to genetic correlations among ecological traits

Efficacy and safety of two different galenic formulations of a transdermal clonidine system in the treatment of hypertension

Fetal Growth Restriction Is Associated With Prioritization of Umbilical Blood Flow to the Left Hepatic Lobe at the Expense of the Right Lobe

A double-blind comparison of transdermal clonidine and oral captopril in essential hypertension

Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure

Computational Prediction of the Protonation Sites of Ac-Lys-(Ala)n-Lys-NH2 Peptides through Conceptual DFT Descriptors

Patient acceptance of transdermal clonidine. A retrospective review of 25 patients

One year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension--a multicentre open label study. The Antihypertensive Patch Italian Study (APIS) Investigators

Effects of transdermal clonidine in young and elderly patients with mild hypertension: evaluation by three noninvasive methods of blood pressure measurement

Accelerated Thermal Cycling Test of Microencapsulated Paraffin Wax/Polyaniline Made by Simple Preparation Method for Solar Thermal Energy Storage

An Architecture and Formalism for Handling Modular Ontologies

Efficacy and tolerability of long-acting nifedipine GITSOROS monotherapy or combination therapy in hypertensive patients: Results of a 12-week international, prospective, multicentre, observational study

Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL)

Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS